Despite the widespread use of young transgenic AD mouse models (7–8 months old) in animal studies, which can mimic the pathological defects of AD in terms of Aβ deposition and NFT tau pathology, they did not exhibit neurodegeneration. The gene discussed is MAPT; the disease is Alzheimer disease.